Local implantation of autologous mononuclear cells from bone marrow and peripheral blood for treatment of ischaemic digits in patients with connective tissue diseases

Rheumatology

Volumn 46, Issue 5, 2007, Pages 882-884

  Kamata, Yasuyuki ^a   Takahashi, Y ^a   Iwamoto, M ^a   Matsui, K ^a   Murakami, Y ^a   Muroi, K ^a   Ikeda, U ^a   Shimada, K ^a   Yoshio, T ^a   Okazaki, H ^a   Minota, S ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Bone marrow mononuclear cell; CD34 positive cell; Connective tissue disease; Peripheral mononuclear cell

Indexed keywords

PROSTAGLANDIN; CD34 ANTIGEN;

ADULT; AGED; ANALGESIA; ANGIOGENESIS; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; FEMALE; FINGER; HUMAN; INTERMETHOD COMPARISON; LIMB ISCHEMIA; MALE; MICROVASCULAR ISCHEMIA; MONONUCLEAR CELL; OPEN STUDY; PATIENT SATISFACTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RATING SCALE; SYNDROME CREST; SYSTEMIC SCLEROSIS; TOE; VASCULAR NECROSIS; BONE MARROW TRANSPLANTATION; DIGITAL SUBTRACTION ANGIOGRAPHY; ISCHEMIA; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RADIOGRAPHY; TREATMENT OUTCOME; VASCULARIZATION;

AGED; ANGIOGRAPHY, DIGITAL SUBTRACTION; ANTIGENS, CD34; BONE MARROW TRANSPLANTATION; CONNECTIVE TISSUE DISEASES; CREST SYNDROME; FEMALE; FINGERS; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TOES; TREATMENT OUTCOME;

EID: 34347269654     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel436     Document Type: Article

References (13)

1. Wollersheim H, VanZwieten PA. Treatment of Raynaud's phenomenon. Eur Heart J 1993;14:147-9.
2. Malamet R, Wise RA, Ettinger WH, Wigley FM. Nifedipine in the treatment of Raynaud's phenomenon. Am J Med 1985;78:602-8.
3. Martin MF, Dowd PM, Ring EF, Cooke ED, Dieppe PA, Kirby JD. Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis. Ann Rheum Dis 1981;40:350-4.
4. Vayssairat M. Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes. J Rheumatol 1996;23:1917-20.
5. Beffour R, Berman J, Garb JL, Rhoe SW, Kaufman J, Friedmann P. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: Dose-response effect of basic fibroblast growth factor. J Vasc Surg 1992;16:81-91.
6. Pu LQ, Sniderman AD, Brassard R et al. Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation 1993;88:208-15.
7. Yanagisawa-Miwa A, Uchida Y, Nakamura F et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992;257:1401-3.
8. Maeda Y, Ikeda U, Shimpo M et al. Adeno-associated virus-mediated vascular endothelial growth factor gene transfer into cardiac myocytes. J Cardiovasc Pharmacol 2000;36:438-43.
9. Shimpo M, Ikeda U, Maeda Y et al. AAV-mediated VEGF gene transfer into skeletal muscle stimulates angiogenesis and improves blood flow in a rat hindlimb ischemia model, Cardiovasc Res 2002;53:993-1001.
10. Tateishi-Yuyama E, Matsubara H, Murohara T et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet 2002;360:427-35.
11. Ferrante A, Thong YH. Optimal conditions for simultaneous purification of mononuclear and polymorphonuclear leucocytes from human blood by the Hypaque-Ficoll method. J Immunol Methods 1980;36:109-17.
12. Breivik EK, Bjomsson GA, Skovlund E. A comparison of pain rating scales by sampling from clinical trial data. Clin J Pain 2000;16:22-8.
13. Del Papa N, Quirici N, Soligo D et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 2006;54:2605-15.